Formycon AG provided earnings guidance for the year 2023. For the year, the company expects a significant increase of revenues compared to fiscal 2022, resulting from revenue and earnings contributions from the commercialization of the Lucentis biosimilar (FYB201) Ranivisio^3/Ongavia^4 /CIMERLI^5 as well as anticipated milestone payments for the FYB202 project.